The Effectiveness Of Intravenous TXA on Reducing Perioperative Blood Loss For Patients Undergoing PAO
Primary Purpose
Bleeding
Status
Withdrawn
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Tranexamic Acid
Normal saline
Sponsored by

About this trial
This is an interventional treatment trial for Bleeding focused on measuring Tranexamic Acid, Periacetabular Osteotomy, Bleeding
Eligibility Criteria
Inclusion Criteria:
- ASA 1-2
- Age 13-35 years
- Scheduled for primary unilateral PAO +/- arthroscopy
Exclusion Criteria:
- Hematologic disorder, thrombocytopenia (Platelet count <140,000/uL3)
- Major hepatic, renal, or vascular disorder
- Active Thromboembolic disorder
- Color vision defect
- TXA allergy
- Taking anticoagulants or antiplatelet drugs (heparin, warfarin, clopidogrel)
- Ethical and/or religious objection to receiving blood products
- International patients
- Patients undergoing revision surgery
- Patients undergoing combined PAO and other surgeries such as surgical dislocation, proximal femoral osteotomy
Sites / Locations
- Boston children hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
Normal saline placebo
Intravenous Tranexamic acid
Arm Description
the participant will get saline 0.9% intravenous infusion for the duration of the surgery
Intravenous TXA will be given as a loading dose over 15 minutes of 30 mg/kg bolus (within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery
Outcomes
Primary Outcome Measures
Blood loss
ml
Secondary Outcome Measures
Plasma TXA level
ug/mL
Full Information
NCT ID
NCT03823417
First Posted
January 29, 2019
Last Updated
October 2, 2019
Sponsor
Boston Children's Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03823417
Brief Title
The Effectiveness Of Intravenous TXA on Reducing Perioperative Blood Loss For Patients Undergoing PAO
Official Title
The Effectiveness Of Intravenous Tranexamic Acid (TXA) on Reducing Perioperative Blood Loss For Patients Undergoing Periacetabular Osteotomy (PAO): A Randomized Double Blind Placebo Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
October 2019
Overall Recruitment Status
Withdrawn
Why Stopped
Investigators decided not to begin the study.
Study Start Date
July 2019 (Anticipated)
Primary Completion Date
July 23, 2019 (Actual)
Study Completion Date
July 23, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Boston Children's Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
In this research study the investigators want to learn more about how a medication called tranexamic acid (TXA) could help reduce bleeding during Periacetabular Osteotomy (PAO) surgery. TXA is approved by the Food and Drug Administration (FDA) for the reduction of bleeding for many types of surgical procedures. TXA works by slowing the breakdown of blood clots and helps to prevent bleeding. From previous studies, TXA has been shown to effectively prevent bleeding in patients undergoing heart, spine and skull remodeling surgeries.
As PAO surgery has been associated with significant blood loss when compared to other types of joint surgeries. In order to try and avoid bleeding that may lead to complications, different strategies can be used. In this research study the investigators want to learn more about how a medication called tranexamic acid (TXA) could help reduce bleeding during PAO surgery.
Detailed Description
This prospective randomized placebo controlled double blind trial will enroll 80 adolescents and young adults undergoing elective peri-acetabular osteotomy (PAO). The primary aim is to determine if intravenous infusion of TXA during surgery is effective compared to standard care (no TXA) in decreasing blood loss (measured; and calculated) and blood transfusion (autologous and allogenic) perioperatively in adolescents and young adults presenting for PAO surgery. The rate of blood loss over time will be measured and compared between groups with adjustment for length of surgery (time; hours) and body weight (kg).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bleeding
Keywords
Tranexamic Acid, Periacetabular Osteotomy, Bleeding
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Patients who choose to participate will be randomized to receive either:
placebo i.e. saline 0.9% (intravenous injection) (Control Group) or
intravenous TXA given as a loading dose over 15 minutes of 30 mg/kg bolus (within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Normal saline placebo
Arm Type
Placebo Comparator
Arm Description
the participant will get saline 0.9% intravenous infusion for the duration of the surgery
Arm Title
Intravenous Tranexamic acid
Arm Type
Experimental
Arm Description
Intravenous TXA will be given as a loading dose over 15 minutes of 30 mg/kg bolus (within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery
Intervention Type
Drug
Intervention Name(s)
Tranexamic Acid
Other Intervention Name(s)
TXA
Intervention Description
Intravenous TXA given as a loading dose over 15 minutes of 30 mg/kg bolus (within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery
Intervention Type
Drug
Intervention Name(s)
Normal saline
Other Intervention Name(s)
placebo
Intervention Description
Normal saline infusion
Primary Outcome Measure Information:
Title
Blood loss
Description
ml
Time Frame
1 week after surgery
Secondary Outcome Measure Information:
Title
Plasma TXA level
Description
ug/mL
Time Frame
24 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
13 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
ASA 1-2
Age 13-35 years
Scheduled for primary unilateral PAO +/- arthroscopy
Exclusion Criteria:
Hematologic disorder, thrombocytopenia (Platelet count <140,000/uL3)
Major hepatic, renal, or vascular disorder
Active Thromboembolic disorder
Color vision defect
TXA allergy
Taking anticoagulants or antiplatelet drugs (heparin, warfarin, clopidogrel)
Ethical and/or religious objection to receiving blood products
International patients
Patients undergoing revision surgery
Patients undergoing combined PAO and other surgeries such as surgical dislocation, proximal femoral osteotomy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Susan Goobie, MD, FRPCP
Organizational Affiliation
Boston Children's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Boston children hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
26354175
Citation
Maruyama M. CORR Insights((R)): Does Tranexamic Acid Reduce Blood Loss and Transfusion Requirements Associated With the Periacetabular Osteotomy? Clin Orthop Relat Res. 2015 Nov;473(11):3602-3. doi: 10.1007/s11999-015-4455-y. Epub 2015 Sep 9. No abstract available.
Results Reference
background
PubMed Identifier
15791100
Citation
Sethna NF, Zurakowski D, Brustowicz RM, Bacsik J, Sullivan LJ, Shapiro F. Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology. 2005 Apr;102(4):727-32. doi: 10.1097/00000542-200504000-00006.
Results Reference
background
PubMed Identifier
21364458
Citation
Goobie SM, Meier PM, Pereira LM, McGowan FX, Prescilla RP, Scharp LA, Rogers GF, Proctor MR, Meara JG, Soriano SG, Zurakowski D, Sethna NF. Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial. Anesthesiology. 2011 Apr;114(4):862-71. doi: 10.1097/ALN.0b013e318210fd8f.
Results Reference
background
PubMed Identifier
25991434
Citation
Wingerter SA, Keith AD, Schoenecker PL, Baca GR, Clohisy JC. Does Tranexamic Acid Reduce Blood Loss and Transfusion Requirements Associated With the Periacetabular Osteotomy? Clin Orthop Relat Res. 2015 Aug;473(8):2639-43. doi: 10.1007/s11999-015-4334-6. Epub 2015 May 20.
Results Reference
background
PubMed Identifier
30609198
Citation
Goobie SM, Gallagher T, Gross I, Shander A. Society for the advancement of blood management administrative and clinical standards for patient blood management programs. 4th edition (pediatric version). Paediatr Anaesth. 2019 Mar;29(3):231-236. doi: 10.1111/pan.13574.
Results Reference
background
PubMed Identifier
30516625
Citation
Goobie SM, Zurakowski D, Glotzbecker MP, McCann ME, Hedequist D, Brustowicz RM, Sethna NF, Karlin LI, Emans JB, Hresko MT. Tranexamic Acid Is Efficacious at Decreasing the Rate of Blood Loss in Adolescent Scoliosis Surgery: A Randomized Placebo-Controlled Trial. J Bone Joint Surg Am. 2018 Dec 5;100(23):2024-2032. doi: 10.2106/JBJS.18.00314.
Results Reference
background
PubMed Identifier
29120963
Citation
Johnson DJ, Johnson CC, Goobie SM, Nami N, Wetzler JA, Sponseller PD, Frank SM. High-dose Versus Low-dose Tranexamic Acid to Reduce Transfusion Requirements in Pediatric Scoliosis Surgery. J Pediatr Orthop. 2017 Dec;37(8):e552-e557. doi: 10.1097/BPO.0000000000000820.
Results Reference
background
PubMed Identifier
28696996
Citation
Goobie SM, Frank SM. Tranexamic Acid: What Is Known and Unknown, and Where Do We Go From Here? Anesthesiology. 2017 Sep;127(3):405-407. doi: 10.1097/ALN.0000000000001788. No abstract available.
Results Reference
background
Learn more about this trial
The Effectiveness Of Intravenous TXA on Reducing Perioperative Blood Loss For Patients Undergoing PAO
We'll reach out to this number within 24 hrs